Personalized care to prevent heart damage from chemotherapy
Individualized medicine to predict and prevent chemotherapy-related heart failure
This project uses patients' genetic information and drugs that block TRPC6 to help prevent heart failure in adults getting doxorubicin for breast cancer or lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-11099783 on NIH RePORTER |
What this research studies
Researchers will use genetic testing to find variants (like those in TRPC6) that raise the risk of heart damage from anthracycline chemotherapy. They will study how those variants affect heart cells grown from patient-derived stem cells and in mouse models to understand how TRPC6 causes injury. The team will test whether blocking TRPC6 protects heart cells and tumors in the lab and animals. The goal is to combine genetic risk scores and targeted therapies so clinicians can personalize cancer treatment to lower the chance of chronic heart failure.
Who could benefit from this research
Good fit: Adults receiving or planning to receive doxorubicin (an anthracycline) for breast cancer or lymphoma are the most likely candidates for this work.
Not a fit: People not treated with anthracycline chemotherapy, children, or patients whose heart failure is already advanced and irreversible may not benefit from these approaches.
Why it matters
Potential benefit: If successful, this work could let doctors predict who is at high risk for chemotherapy-related heart failure and offer treatments to prevent heart damage so patients can safely receive needed cancer therapy.
How similar studies have performed: Early genetic, cell-based, and mouse studies by these and other investigators suggest TRPC6 inhibition can protect the heart, but human clinical evidence is not yet established.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Norton, Nadine — Mayo Clinic Jacksonville
- Study coordinator: Norton, Nadine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.